Switzerland
· Delayed Price · Currency is CHF Molecular Partners AG Statistics
Total Valuation
Molecular Partners AG has a market cap or net worth of CHF 176.94 million. The enterprise value is 36.07 million.
| Market Cap | 176.94M |
| Enterprise Value | 36.07M |
Important Dates
The last earnings date was Friday, October 25, 2024.
| Earnings Date | Oct 25, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Molecular Partners AG has 36.86 million shares outstanding. The number of shares has increased by 1.02% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 36.86M |
| Shares Change (YoY) | +1.02% |
| Shares Change (QoQ) | +0.04% |
| Owned by Insiders (%) | 4.43% |
| Owned by Institutions (%) | 11.95% |
| Float | 7.17M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 26.41 |
| PB Ratio | 1.15 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.58 |
| EV / Sales | 6.01 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.57 |
Financial Position
The company has a current ratio of 14.33, with a Debt / Equity ratio of 0.02.
| Current Ratio | 14.33 |
| Quick Ratio | 14.08 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.04 |
| Interest Coverage | -2,335.96 |
Financial Efficiency
Return on equity (ROE) is -37.37% and return on invested capital (ROIC) is -23.07%.
| Return on Equity (ROE) | -37.37% |
| Return on Assets (ROA) | -21.17% |
| Return on Capital (ROIC) | -23.07% |
| Revenue Per Employee | 35,726 |
| Profits Per Employee | -372,565 |
| Employee Count | 168 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +29.72% in the last 52 weeks. The beta is 0.61, so Molecular Partners AG's price volatility has been lower than the market average.
| Beta (5Y) | 0.61 |
| 52-Week Price Change | +29.72% |
| 50-Day Moving Average | 4.70 |
| 200-Day Moving Average | 4.60 |
| Relative Strength Index (RSI) | 46.41 |
| Average Volume (20 Days) | 28,990 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Molecular Partners AG had revenue of CHF 6.00 million and -62.59 million in losses. Loss per share was -1.90.
| Revenue | 6.00M |
| Gross Profit | -43.96M |
| Operating Income | -63.07M |
| Pretax Income | -62.59M |
| Net Income | -62.59M |
| EBITDA | -62.16M |
| EBIT | -63.07M |
| Loss Per Share | -1.90 |
Balance Sheet
The company has 143.62 million in cash and 2.75 million in debt, giving a net cash position of 140.87 million or 3.82 per share.
| Cash & Cash Equivalents | 143.62M |
| Total Debt | 2.75M |
| Net Cash | 140.87M |
| Net Cash Per Share | 3.82 |
| Equity (Book Value) | 138.78M |
| Book Value Per Share | 4.18 |
| Working Capital | 139.10M |
Cash Flow
In the last 12 months, operating cash flow was -62.04 million and capital expenditures -867,000, giving a free cash flow of -62.91 million.
| Operating Cash Flow | -62.04M |
| Capital Expenditures | -867,000 |
| Free Cash Flow | -62.91M |
| FCF Per Share | -1.71 |
Margins
| Gross Margin | n/a |
| Operating Margin | -1,050.83% |
| Pretax Margin | -1,042.84% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -1,048.12% |
Dividends & Yields
Molecular Partners AG does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.02% |
| Shareholder Yield | -1.02% |
| Earnings Yield | -39.48% |
| FCF Yield | -35.55% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Molecular Partners AG has an Altman Z-Score of 3.16.
| Altman Z-Score | 3.16 |
| Piotroski F-Score | n/a |